BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
May 25, 2009
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 5/22 cls
Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) JMP Securities Liisa Bayko Downgrade Underperform (from market perform) 20% -$1.29
Bayko set a $1 target after Gilead (NASDAQ:GILD) returned rights to GS-9252/ACH-1095, an HCV non-structural protein 4A antagonist in preclinical development to treat HCV.
Biogen Idec Inc. (NASDAQ:BIIB) Barclays Capital Jim Birchenough Upgrade Equal weight(from underweight) 3% $50.39
Birchenough raised his target to $52 from $40 after Biogen Idec said weekly trends for utilization of Tysabri natalizumab for multiple sclerosis (MS) had improved in March and April over average trends in 1Q09. He also raised his FY09 EPS estimate to $4.15...

Read the full 774 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >